Table 2. . Estimated cost of hematologic AE management using November 2021 data cut-off date.

Hematologic AE	Frequency of grade ≥3 AE in patients treated with niraparib, n (%)		AE unit cost†	Mean calculated cost per patient‡
	FSD (n = 315)	ISD (n = 169)		FSD	ISD
Thrombocytopenia§	155 (49.2)	37 (21.9)	$12,992.00	$6392.82	$2844.40
Anemia	114 (36.2)	39 (23.1)	$7830.00	$2833.71	$1806.92
Neutropenia¶	78 (24.8)	25 (14.8)	$14,466.00	$3582.06	$2139.94
Total cost				$12,808.66	$6791.27

^†Cost in the US adjusted to 2020 US dollars.

^‡Costs calculated using the unrounded frequency of grade ≥3 AEs.

^§Includes platelet count decreased.

^¶Includes neutrophil count decreased.

AE: Adverse event; FSD: Fixed starting dose; ISD: Individualized starting dose.